TrialConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Trial details
- Registry ID
- NCT06500273
- Phase
- Phase 2
Drug research
Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity has not yet been verified against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLNCT06500273 | Allogene Therapeutics | Phase 2 | Recruiting | 2027-12Estimated |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |